From the publishers of JADPRO

Multiple Myeloma Resource Center

Advertisement

Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma

Last Updated: Friday, March 29, 2024

A phase 3 trial of 709 transplantation-eligible patients with newly diagnosed multiple myeloma found that the addition of subcutaneous daratumumab to bortezomib, lenalidomide, and dexamethasone induction and consolidation therapy and to lenalidomide maintenance therapy presented a significant benefit regarding progression-free survival among these patients.

The New England Journal of Medicine
Advertisement
News & Literature Highlights
Advertisement
Advertisement